Supply chain pressure can pose serious risk to pharma, experts argue
CPhI Worldwide, part of UBM Live’s Pharmaceutical Portfolio, has released the final part of its 2014 annual report. Three experts have each examined the pharma industry, particularly from a supply chain and contract services perspective, providing analysis on how this market will adapt and grow.
Biotechs are ‘looking for an exit’
Hedley Rees, managing director at PharmaFlow, said he believes that one of the major problems that currently exists within the pharmaceutical development industry is that many biotechs and virtual companies are simply ‘looking for an exit’ part way through development and larger companies are only looking to develop proven products, resulting in a severe ‘commitment dilution’ that is slowing down and hindering innovation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze